Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats

Acta Pharmacologica Sinica

Volumn 18, Issue 1, 1997, Pages 71-74

  Yu, Feng ^a   Dai, De Zai ^a   An, Lu Fan ^a   Guo, Xiu Fang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

action potentials; arrhythmia; heart hypertrophy; levothyroxine; malondialdehyde; myocardial infarction; papillary muscles; superoxide dismutase

Indexed keywords

LEVOTHYROXINE; LIDOCAINE; MALONALDEHYDE; PROPAFENONE; PROPRANOLOL; SUPEROXIDE DISMUTASE; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE; HEART ARRHYTHMIA; HEART HYPERTROPHY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART PAPILLARY MUSCLE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; REPERFUSION INJURY; TISSUE LEVEL;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; CARDIOMEGALY; DISEASE MODELS, ANIMAL; FEMALE; MALE; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, SPRAGUE-DAWLEY; THYROXINE;

EID: 0031037588     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Dai DZ. Drugs remodelling structure of cardiovascular system. Adv Pharm Sci 1992; 16: 129-33.
2. Kohya T, Kimura S, Myerburg RJ, Bassett AL. Susceptibility of hypertrophied rat hearts to ventricular fibrillation during acute ischemia. J Mol Cell Cardiol 1988; 20: 159-68.
3. Morgan HE, Gordon EE, Kira Y, Chua HL, Russo LA, Peterson CJ, et al. Biochemical mechanisms of cardiac hypertrophy. Annu Rev Physiol 1987; 49: 533-43.
4. Miyazawa K, Hashimoto H, Uematsu T, Nakashima M. Electrophysiological abnormalities and enhanced reperfusion arrhythmias in the isolated hearts of hyperthyroid rats. Br J Pharmacol 1989; 97: 1093-100.
5. Dai DZ, Rong P, Huang J, Liu J, Cheng JH, Chen YH, et al. Anti-arrhythmic activities of six indole derivatives of changrolin. Acta Pharmacol Sin 1991; 12: 411-5.
6. Harron DW, Brezina M, Lillie C, Kobinger W. Antifibrillatory properties of alinidine after coronary artery occlusion in rats. Eur J Pharmacol 1985; 110: 301-8.
7. Li SR, Li ZW, Lu JT. Action potential of cardiac myocyte recorded by floating microelectrode. In: Zhou XS, Zhao YQ, Wang RY, editors. Methods and techniques of physiology; vol 2. Beijing: Science Press, 1984: 1-23.
8. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-8.
9. Tosaki A, Balint S, Szekeres L. Protective effect of lidocaine against ischemia and reperfusion-induced arrhythmias and shifts of myocardial sodium, potasium and calcium content. J Cardiovas Pharmacol 1988; 12: 621-8.
10. Mann DL, Spann JF, Cooper G IV. Basic mechanisms and models in cardiac hypertrophy: Part 2. hypertrophy to failure. Modern Concept Cardiovasc Disease 1988; 57: 13-8.